The Royal Society of Edinburgh (RSE) is pleased
to respond to the Foresight Healthcare Panel's consultation on Healthcare
in 2020. The RSE is Scotland’s premier Learned Society, comprising
Fellows elected on the basis of their distinction, from the full range
of academic disciplines, and from industry, commerce and the professions.
This response has been compiled by the General Secretary with the assistance
of a number of Fellows with substantial experience of medicine and health
research and provision from across Scotland and the UK.
The specific questions identified in the consultation document are
addressed below:
SECTION 1 - DEMAND AND THE BURDEN OF ILL HEALTH
Under what circumstances might technological progress result
in reduced rather than increased demand for health care at least in
certain groups. How might it be demonstrated and what account of it
should be taken in forming health policy?
It is highly likely that there will be progressive and continuing changes
in the demands for healthcare but that it is most unlikely that demand
for healthcare will reduce. The view that new developments could decrease
the burden of disease on the Health Service was the original concept
with which Aneurin Bevan began the National Health Service (NHS). However,
it has proved to be unfounded. Improving healthcare, developing new
treatments for previously untreatable diseases, with antibiotics for
example, has in general changed the spectrum of disease but it does
not appear to have reduced the amount. In fact, the public expectation
of health benefit is probably higher now than ever before.
In addition, as the population ages the time at which demand for healthcare
will become greater will be amongst the elderly in our population and
there is every indication that the demands for healthcare will rise
as more and more people live for greater years. The demand for healthcare
will be in many areas but particularly relating to orthopaedics (hip
and knee replacements etc), eyesight, hearing, dementia and degenerative
disorders. There is a clear evidence of rising levels of maturity-onset
diabetes which will lead to problems of vascular disease leading to
the need for treatment of vascular disease either of the heart, the
limbs or in other sites.
Demand will fall, however, for conditions whose prevalence and incidence
can be confidently predicted to decline over the next 20 years, for
example for peptic ulcers secondary to Helicobacter pylori infection.
What steps might be taken to integrate health promotion,
disease prevention and clinical medicine and how might such an integrated
function be piloted?
Disease prevention and sickness services could be integrated through
a long-term commitment to health education. This should start in childhood
and be taken out to the community through local networks. In medicine,
integration is present to some extent in primary care through General
Practitioners (GPs) and their role is important because of their great
influence over their patients (for example, in persuading a doubtful
mother to have her child immunised with MMR). Many GPs do, however,
require better training in disease prevention and the potential benefit
of health education. The role of other health care professionals, such
as pharmacists and nurses, should also be considered, together with
changes in undergraduate/postgraduate medical curricula through the
inclusion of multi-professional training.
Thought should be given to piloting schemes where personnel might be
jointly trained within a subject (e.g. communicable diseases) to produce
the opportunity for better understanding and appreciation of ways to
approach the prevention and management of the condition. An integrated
planning and monitoring scheme has also been undertaken for heart disease
in one or two places in England, under the Purchasing Development Project
(Academy of Medical Royal Colleges; 1997).
How best can social services, health care and the education
sector link to ensure that requirements for the health of children are
fulfilled?
An integrated network of services could be established to target prenatal
and pre-school age children and their parents. There could also be support
in the community for parents, particularly single parents, making provision
for training and retraining of parents in a variety of skills alongside
play and education for children. Local multidisciplinary teams involving
Social Services, Healthcare and Education might also be piloted in selected
areas.
Can tax and other incentives facilitate strong linkages
between health care and other sectors? What is the precise rationale
of such linkages and what are the implications for academia, industry
and government? How best can the potential for health gain be incorporated
into public policies across a range of sectors?
An effective strategy requires commitment and participation rather than
incentives. However, taxation could be an important way of influencing
the linkages between health care and other sectors by giving financial
encouragement to promising developments. In terms of the implications
for the private sector, it is possible that employers may take account
of these factors in assessing the likely future fitness of potential
employees so that on the one hand the socially disadvantaged may find
their employment opportunities deteriorating. On the other hand individuals
who avoid smoking, obesity, and other readily identifiable causes of
ill health may enjoy better employment opportunities and this will have
an effect on health-related behaviour. It may also have an impact in
the area of health insurance with reduced subscriptions for people who
take responsibility for their own health. For example in Germany, women
who have an annual cervical screen get reduced insurance as opposed
to those who do not.In terms of the incorporation of health gain into
public policies across a range of sectors, there is strong evidence
from several countries, including the UK, that the proportion of total
disposable income going to the poorest group of the population has a
major influence on life expectancy. There could be consideration, therefore,
for some form of "Health Impact Assessment", analogous to
the existing Environmental Impact Assessment.
Taking into account trends in science and technology and
other changes, for example in demography and population movement, what
will the most likely new and expanded demands for health care in the
UK be over the next twenty years?
Increasing trends towards longevity, lack of exercise and obesity all
suggest that the major expanding health demands will be in the fields
of regenerative services (such as bioengineering) and degenerative diseases
(such as cardiovascular, orthopaedic and probably dementia). In addition,
the increase of stress-related illnesses, antibiotic resistant infections
and the expansion of "tropical" diseases into temperate regions
due to global warming, food contamination and increasing travel world
wide are also issues likely to impact significantly on health. Treatments
for conditions, particularly genetic diseases, that are presently considered
intractable, using approaches such as gene therapy and stem cell therapy,
may also be sought. However, many of today's diseases are likely to
continue to cause considerable health burdens in 2020
In relation to likely advances in genetics and other fields
how might demands for screening change and how might health care be
structured to accommodate these changes in a responsive but orderly
way?
It is clear that both molecular and symptomatic screening for those
who may be genetically susceptible to common cancers are facing increasing
demands and this is likely to extend also to other common diseases with
identifiable genetic components, such as diabetes and degenerative cardiovascular
disease. Genetic predisposition to disease and of pre-disease factors
are likely to become important and the tailoring of treatments to an
individual's genetic constitution, initially by screening for genotype
at particular loci, may develop. A key consideration will be the ethical
problems involved in such screening. These issues are addressed further
in the Society's response on Preimplantation Genetic Diagnosis.
The principles that underline decisions to set up future screening
programmes remain unchanged: the disease is common and of consequence,
there is an effective screening test (irrespective of its nature), and
early treatment favourably alters the outcome. The existing and future
national screening programmes within the various regions should be co-ordinated
and monitored more effectively through a central agency to detect problems
and poor performance before these enter the public domain. Demands for
screening, however, are likely to increase, with a risk that failure
to screen will be perceived as negligence and a need to tackle the ethical
question of who is entitled to have access to the information, particularly
in connection with medical insurance.
There are impressive technological developments that will make automated
screening a real possibility in the foreseeable future, though it is
currently difficult todecide where major investments should be directed,
since today's technology can rapidly be superseded by faster and cheaper
alternatives that require different types of hardware. Nevertheless,
the NHS should be prepared to make major investments in appropriate
hardware relatively soon. The other essential component is a pool of
trained professionals such as clinical geneticists (who need not necessarily
be medical practitioners) to advise both patients themselves and their
doctors on the clinical implications of genetic information. There is
very good evidence now that appropriately trained nurses can fulfil
this function effectively and there is a need to expand the number of
training courses and provide a proper career structure for these professionals
within the NHS.
What steps might be taken to achieve proactive health care
and to set in place chronic disease services?
A proactive approach to health care could include relevant screening,
prophylactic therapy when available, education of relatives and the
general public in dealing with the elderly, and ensuring that people
get sufficient exercise from middle age onwards. In addition, there
should be a wider range of properly integrated services that cover functions
currently undertaken, for example, by the home-help system, residential
care and nursing care services.
What will be the social and health care needs of the elderly
by 2020 and how might these be met?
By 2020 the social and health care needs of the elderly are likely to
be much increased. The relationship between social services and the
health services is intimate and the two must be dealt with in parallel.
Adequate facilities and resourcing of the care of the elderly (either
in the community or in suitable institutions) is a very important provision
to ensure that the acute health services are not rendered less efficient
than they should otherwise be because of the burden of unmet social
needs.
There are likely to be increased requirements for purpose built accommodation,
better facilities etc. However, although maintenance of the elderly
in their own homes is often the best option, the likely rise of IT support
mechanisms and surveillance of old people in their homes may lead to
isolation and increasing mental problems. More specialists, psychologists
and psychotherapists, community care workers and "friends"
will, therefore, be required to maintain mental health and physical
independence of elderly people. However, it is possible that by 2020
there will be a pharmaceutical means of either delaying or even preventing
the onset of Alzheimer's disease. A more proactive and flexible approach
to retirement should also be taken by all businesses.
How might the UK exploit its science base more effectively
to take a lead in fighting infectious disease, for example by developing
vaccines based on nucleotide and T-cell technology?
To a large extent the UK has downgraded its infectious disease and laboratory
services so that it has lost much of the pre-eminence it had in the
past. There is, therefore, a need for the UK to devote a higher priority
to developing vaccines and to providing the necessary funding. Commissioned
research should be undertaken both in universities and by industry,
although much of the research into vaccines based on nucleotide and
T-cell technology is currently financed by the pharmaceutical industry.
How can the UK build on its track record in public health
to ensure that more effective European and wider international surveillance
Infectious disease does not respect national boundaries. International
co-operation in surveillance is already quite good, but largely based
on informal arrangements. There may be a role for a EU body to co-ordinate
the exchange of information within Europe, perhaps with rapid response
teams who are in place to both validateand contain outbreaks of disease
which threaten to become epidemics. There will, however, be a need to
clarify the rules on constructing and using effective healthcare databases,
the development of which are presently restricted by the lack of clarity
surrounding issues of individual privacy versus the public good.
SECTION 2 - ORGANISATION AND WORKFORCE
In what way might the voluntary sector play a larger and
more decisive role in the health care of 2020?
The voluntary sector is likely to play an important and expanding part
in promoting awareness of health-related strategies, particularly for
prevention and reducing risk, and requires recognition, support and
networking. However, its role should be complementary to, and not competitive
with, that of the NHS.
Who and how will patients be directed to the appropriate
expertise - by health advocates, web-sites, primary care physicians,
nurses or support networks of lay people?
Specialisation in medicine has been increasing for 100 years and will
continue to do so. There is no reason why the primary healthcare team,
including general practitioners and practice nurses, should not remain
the key to appropriate direction of patients to specialist facilities.
Indeed, the "gatekeeper" role of the GP is an important reason
for the relative cost-effectiveness of the NHS. There may, however,
also be a role for primary care physicians to use NHS developed/approved
web sites to direct patients to the appropriate expertise.
On the basis of current trends professional roles are likely
to be transformed over the next twenty years.
What might the characteristics and distinctions between
different health professions and between professional and other staff
be in 2020?
The Health Service in the United Kingdom has traditionally been manned
by a diversity of professions - medical, nursing, scientific etc. Necessary
as it is to have the very best of expertise in these various areas of
work - and the amalgam of the various disciplines when it works well
can produce extraordinarily good results - nevertheless these divisions
have occasionally led to rivalry and misunderstanding between different
groupings which in turn has led to a diminution of efficiency and effectiveness
in the Health Service as a whole. A start seems to have been made to
dismantle some of the high walls which surround the various professions.
For example, nursing staff now have the opportunity to undertake tasks
which were until recently restricted to medically qualified staff.
It is imperative that the work is of the highest standard but by 2020
it is to be hoped that this sharing of responsibilities will have become
much more frequent and, even within the different professions, there
will be a similar restructuring of traditional involvement of personnel
to produce more imaginative and cost efficient health care. The distinction
between existing disciplines within the hospital sector, for example,
could be blurred by the emerging medical interventional technology with
the development of disease-specific multidisciplinary treatment groups
covering both community and hospital care. This assumes the need for
a triage system, which could well be served by community nurses with
the right training. The existing distinction between community, ambulatory
and in-hospital care could also be gradually phased out.
The current training programmes of the various disciplines, however,
will need drastic revision and this must incorporate multi-professional
training. Indeed, it may be manpower shortage that will be the principal
driver for the blurring between professional boundaries, rather than
technology, given the shortage of students opting for science as a career
and the planned expansion of medical places. These changes will therefore
require careful management and control, particularly in terms of the
maintenance and testing of professional competence.
Might general medical practitioners evolve into community-based
specialists and might the generalist role be assumed by nurses and other
non-medical staff?
Nurses and other non-medical staff are likely to perform increasingly
useful roles, including becoming experts in the management of particular,
often narrowly defined, conditions, but this should only be within GP
led teams. The generalist role of the GP and his or her ability to diagnose
illness across the whole range of medicine and to understand at least
the principles of treatment across that broad span are crucial.
Might the distinction between treatment providers and carers
become blurred as technologies impact on human roles and shape the delivery
of care?
While there is a close link between treatment providers and carers,
in practice, there are often different skills involved and some will
be more drawn to one aspect than the other.
Might the social aspects of health care become a speciality
in itself perhaps with a new cadre of community and possibly hospital-
based carers?
A new type of social worker, employed by the NHS and working as a member
of the primary care team, could be an attractive idea and pilot studies
should be carried out and evaluated.
What will be the education, training and professional development
needs of healthcare providers?
To ensure that the workforce are properly equipped to meet the challenges
of the future there is a major need for investment in training and learning.
There is at present a significant gap between the needs of the workforce
in healthcare and what is actually being delivered in practice. This
is particularly true in nursing and professions allied to medicine.
The provision of training in medicine is better but even there more
needs to be done to bring the levels of continuing professional development
up to what is needed. The needs for training will also expand as new
processes such as revalidation come into place. The single most important
issue to address in respect of education and training is the provision
of time by senior staff to supervise their junior colleagues as they
acquire their new skills. Excessive pressure on the workforce inevitably
means that the training function is squeezed out and done less effectively
than it should be.
How can the dependence of UK healthcare on imported staff
be both justified and managed in the future? How can we ensure that
those who come from developing countries receive training appropriate
to the needs of the countries from which they originate? How can we
make better use of the untapped resources present amongst refugees and
asylum seekers who include many health professionals?
The importation of staff to the NHS has produced many benefits to both
the service and to the "imported" individual. However, the
recruitment of large numbers of doctors and nurses from developing countries
raises ethical questions in terms of the precious resources that those
developing countries have devoted to training those people, and the
need for their skills in their home countries. In order to realise further
the advantages of imported staff, and to make better use of the skills
of refugees and asylum seekers, there should be a more centralised body
to oversee and speed up the validation and appropriateness of the person
to a particular post and then to arrange for suitable counselling and
training.
Ideally the UK healthcare system should be self-sufficient in terms
of staff. This willrequire a re-look at the pool of staff available
and improved manpower planning, as envisaged in the Department of Health's
recent consultation document 'A Health Service of all the Talents'.
Until recently the number of medical school places in the UK has been
carefully controlled and the current shortage in medical staff is a
result of these (planned) past restrictions. Mechanisms could also be
put in place to attract those staff back to the NHS who have been lost
to the service so that many more people are encouraged to develop satisfying
careers that do not require long-term full-time employment. This would
particularly address wastage among highly (and expensively) trained
women.
How might productive multidisciplinary teamwork evolve
in the future, how might it be mainstreamed in health care and what
incentives are needed to optimise skill sharing to deliver high quality
care?
Up till now team working has mostly just evolved with some participants
being better at it than others. Perhaps the possibility of teaching
this aspect of healthcare activities should be explored and multidisciplinary
teamwork established by design and intent. Greater priority could be
given to teamwork in career progression, which currently depends to
a large extent on competition.
What practical steps can be taken to alleviate and prevent
stress and what in-built features might be envisaged to ensure that
the stress experienced by staff is minimised in future health care?
There are many current sources of stress in healthcare. Many of these
relate to the pace of change, the continuous pressure to make cuts in
every aspect of the healthcare system, overwork and, to a lesser extent,
insensitive management. Advancement in careers is often at the expense
of those elements of work which engender job satisfaction. Staff pay
and declining public esteem are also serious issues.
A solution would be for more staff to be trained as quickly as possible
and, particularly where nurses are concerned, more attention paid to
their retention. A confidential support and stress-reduction network
may also be helpful.
Where should progressive leadership come from and how should
it be developed?
Leadership has to come from the top, including the General Medical Council,
the British Medical Association and the Royal Colleges. In addition
to identifying individuals who have already made their mark in the health
service in the UK, goodprogressive leadership could be sought in areas
of excellence in other countries, such as the United States, with excellent
individuals invited to manage healthcare in a particular area of the
UK and to train the next generation of leaders. Once appointed there
should also be continuous professional development at the highest level.
What steps are needed to achieve interpersonal and listening
skills and what lessons might be drawn from the commercial and other
sectors?
Interpersonal skills need to be developed through education at school,
and during medical and CPD training. However stress and high levels
of job pressure will act as obstacles to their development. Where there
is chronic under-manning, extra training is seen as an irrelevant luxury.
Adaptability and building linkages between disciplines
will be essential futurerequirements. Is there an emerging role for
the intellectual generalist?
Discipline-hopping initiatives will encourage scientists and, possibly
doctors and other healthcare workers, to acquire expertise in different
fields and such staff will be well placed to guide future developments.
Improved communication and teamwork between specialities, however, will
still be the key. One deterrent is that staff see better promotion prospects
within a narrow discipline rather than in a general field.
What safety systems will be needed in the future? How should
these be designed and introduced with appropriate incentives to make
them work?
There should be ready acknowledgement that healthcare systems are never
perfect. The occurrence of errors should be openly acknowledged with
earliest steps taken to put the problem right. Centralised systems of
incident reporting, mortality reviews and patient complaints would identify
problems at an earlier stage, together with more effective audit of
admissions, diagnoses and discharges. There should be a team approach
to identification and rectification of less than ideal practice. This
will help to reduce the present blame culture and encourage early identification
of weaknesses. The public should also be better informed about the balance
of risk versus benefit and consideration should be given to produce
a no fault scheme of compensation when complications arise.
What applicability might incentive structures for optimising
the results of health care and other approaches have in health care?
While the health care system should always be keen to learn from other
organisations care should also be taken to see if the methods used are
appropriate in the medical setting.
What are the arguments for integrating health and social
care, what are the obstacles to achieving integration, and what issues
does this raise for funding and regulation.
The integration of health and social care in Northern Ireland (necessitated
by the absence of elected local authorities) has produced better community
care, and fewer boundary disputes, than in the rest of the UK. Lessons
should be learnt from this and the potential benefits of innovative
and flexible combinations of services are immense (see the report of
the Royal Commission on Long Term Care for the Elderly). It is important,
though, not to create a new boundary between social work and housing
which would be almost as damaging as the present boundary between healthcare
and social work. The flexible combination of services could be facilitated
by the appointment of persons with a liaison responsibility.
How might future health care information requirements be
developed through a balance of central policy and local strategies and
initiatives?
For many diseases (including cancer) it is important to convey lifestyle
information as early as possible and the involvement of health professionals
and bodies such as the Health Education Board for Scotland (HEBS) with
the schools curriculum will aid this, although beneficial consequences
are unlikely by 2020.
Most Information Technology (IT) initiatives in the healthcare environment,
however, tend to be problematic. Manufacturers are often very cautious
about being involved in NHS IT systems as they perceive that requirements
are often poorly specified and there is inadequate project supervision.
There is also the fundamental issue related to the difficulty of transferring
medical data to computer in a reasonable time, and the quality of the
raw data due to entries being made by unqualified, poorly paid and over-stretched
clerical staff. In turn, this relates to salaries and the level of resource
available.
What are the main challenges and opportunities for healthcare
systems presented by the internet revolution and e-commerce?
The internet will have undoubted power in conveying information but
quality control of this source is vital and the internet is unlikely
to achieve high penetration amongst the population who will present
a particular burden in 2020, those currently in the 55-70 age range.
On a more positive vein, centralisation of many services could be undertaken.
Already, for example digitised recordings of electrocardiograms can
be transmitted from anywhere on the internet within a short period of
time to a central facility and interpretations returned within hours,
having been checked by a qualified individual. Similarly, internet-based
services for storing patient records remotely are now being introduced
in North America so that small hospitals do not have to cope with running
a large computer system.
What will be the health information needs of clinicians,
patients and the public and what are the barriers to meeting these needs?
It is likely that clinicians will undertake ward rounds and be able
to check out information on-line to assist with diagnosis and treatment.
This approach, which is already being piloted in Glasgow, can be expected
to grow. In the future, patients may also carry their own stored data
including scans and therefore will be able to benefit from drop-in healthcare
centres more readily. The IT revolution has, however, a risk of depersonalising
the service while making it more efficient.
With the tremendous advances in information technology much more attention
needs to be given not only to the training of the users of the information
but also to those providing it so that the information is as user friendly
as possible. In terms of data protection, the stance of the European
Parliament and of the Data Protection Registrar is that personal information
about patients can only be used for purposes other than their care with
their explicit permission, and only for the purposes for which they
have given permission. If measures are not introduced to address this,
it could potentially pose a serious threat to clinical audit, clinical
governance and many types of research.
Between 1948 and 2000 there has been a consensus that UK
healthcare should be financed collectively for all the population and
distributed according to need. Is this line of reasoning valid or does
it reflect attachment to an outmoded concept?
In general the line of reasoning is valid but it needs to be modernised
for a modern society. Modifications to the health care system will inevitably
continue to happen but a national health service should be the basis
of one of the anchor stones of the UK infrastructure to which adjustments
can be grafted.
While some form of private-public partnership, with the State retaining
final responsibility for equity of access, seems possible, it is certainly
true that the structure and financing of the NHS is a great advantage
in the planning and delivery of preventive medicine. It is equally true
that until the last decade or so these advantages have not been properly
exploited.
How might healthcare be funded in 2020, and might there
be some convergence of funding methods across the EU?
It is true that the UK is unusual in financing so high a proportion
of its total healthcare costs from public funds. A single structure
like the NHS does, however, have inherently lower administrative costs
than the continental insurance-based systems. The common continental
approach, however, of joint funding from taxation and private insurance
contributions seems reasonable for those who can afford it and would
go some way to mitigating the cost of an increasingly costly NHS.
What are the prospects for employers contributing in different
ways to healthcare and what could be incentives for this?
Initiatives such as the smoke-free work place have been important in
this regard and the emphasis for employers should shift away from mere
safety of staff towards a positive attitude towards health. Provision
for rest and relaxation, for exercise, for healthy eating, for enlightened
allowance for leave for care of geriatric dependants as well as child
minding, flexible working and proper preparation for retirement might
be some ways in which employers could contribute indirectly to healthcare
and possibly result in higher productivity and greater employee satisfaction.
What will be the nature, magnitude and impact of health
inequalities in 2020 and what are the drivers that will increase/decrease
these?
In most respects the NHS does provide equity of access and that is one
of its great achievements. It is important to recognise, however, that
no system of healthcare is likely to provide equity of outcome, for
outcomes depend on a wide range of interacting economic and social factors.
The most important of these is probably the distribution of disposable
income in the population.
In addition, the utilisation of technologies such as the internet,
the web and other sophisticated methods of communication will mean that
the well educated may have the means to access health care which might
not be used by the more disadvantaged who find these new methods less
available and less suitable to meet their needs. Modern methods of communication
may, paradoxically, be a major factor in widening even further the healthcare
gap that we see at the present time.
How might the needs of complex multi-ethnic communities
be met?
Language barriers are particularly hard to break down in older people
who are not native English speakers, therefore schemes which educate
parents alongside their children, in school and in a variety of languages
particularly English, are a significant step taken now towards prevention
of these problems in 2020. Along side this, however, specialised liaison
officers could be considered in particular areas.
What steps might be taken to exploit the opportunities
for integrating Telephone and internet-based advice, and walk-in and
work-based clinics into existing systems and avoiding potentially undermining
effects?
Walk-in and work-based clinics could work significantly to reduce dissatisfaction
with the health service and to provide a more efficient healthcare system,
while maintaining work attendance and efficiency. Care would be needed,
however, so that they do not lead to a disruption of the relationship
of the patient to his family doctor. Patients might also carry their
own IT-based records which duplicate a centrally stored system.
With regard to internet-based advice, NHS direct on-line has made an
impressive start. However, other currently unregulated "health
advice" internet services are of extremely variable quality and
some form of accreditation and approval system should be put in place.
What are the barriers to 24-hour services as a permanent
in-built feature of health care?
24-hour services are obviously essential for medical emergencies and
to provide adequate care for people who are critically ill. Their provision
will, however, be expensive and place great demands on clinical staff,
particularly doctors and nurses. 24-hour services could, however, maximise
the efficient use of high-tech facilities such as imaging and operating
theatres. The difficulties with such 24-hour usage may arise due to
possible diurnal variation not only in the energy of healthcare staff
but more subtle parameters in the patient such as cyclical neuroendocrine
and immune functions.
Is this a future in which clinical decisions are supported
by intelligent systems a feasible future picture and if so what might
the hospital including the teaching hospital - of 2020 look like?
It is possible that we will move in the direction indicated but probably
at a much slower pace than might be envisaged, with availability of
manpower being a significant factor. It could, however, lead to a much
more highly selected in-patient population and an increase in specialist
day-treatment services. The movement of technology from the hospital
to the community clinic will also raise the problem of who supports
it, in terms of monitoring the quality of the output (both staff and
equipment), ensuring that it functions well and provides updates as
required.
SECTION 3 - PATIENTS AND PUBLIC
How might the future patient-professional "contract"
or relationship develop and what could be done to take advantage of
changing technologies and attitudes?
It should not be assumed that the internet will necessarily educate
the whole population. However, there will certainly be a cadre of very
well informed patients whose opinions and knowledge should be respected.
There will also be subsets of patients who are misinformed but vociferous
in their demands. The patient-healthcare professional contract should
therefore continue to involve a degree of trust together with an attitude
of openness and acceptance by both doctor and patient that it is impossible
to be familiar with all available data. Properly integrated multidisciplinary
primary healthcare teams could also assist these developments.
One of the problems with current practice is deterioration in the continuity
of clinical care which is inevitably detrimental to the individual patient,
as it is ultimately the individual responsibility of the healthcarer
that protects the patient. The shortened working hours, shift working
and diversification of responsibility anticipated in the Foresight document
could have potential harmful consequences on such continuity. On the
positive side, while consultations may not be face to face, IT contact
may improve continuity of care during travel or other circumstances.
How will systems and roles develop to promote the empowerment
of individuals and communities encouraging local networks and local
solutions?
Public understanding of healthcare issues, information and education
all require a variety of strategies. Mainstream education at all stages
of life remains important but less obvious ways of imparting messages
have proven effective, such as storylines in television "soaps",
popular magazines and role models amongst sports stars. Self-care must
be promoted through schools and work places but is likely to be kept
up only when the health benefits are appreciated.
Will specially skilled staff be needed to advise on genetic
information, to assist with patient choice and the selection of interventions?
The demands for screening services may rise exponentially as understanding
of the genetic basis of disease becomes clearer. The early experience
from genetic screening for breast and ovarian cancer has shown that
the genetic information creates huge levels of anxiety amongst potentially
affected individuals and the demand for expert and sensitive screening
is very large. It will be important to recognise this need clearly and
to train suitable individuals, who need not necessarily be medically
qualified, with the skills to advise on a number of areas where genetic
factors predispose to disease. In addition, GPs and all healthcare staff
will require some basic training in answers to the common questions.
It is vital that the quality of the screening operation is maintained
at a high level and regularly maintained.
What incentives and mechanisms might be set in place to
attract public interest in scientific and technical issues and to encourage
clinicians and scientists to become actively engaged in public discussion?
Public interest in science should be engaged at the level of school
by making science accessible, interesting and fun. Public enterprises,
such as science centres, which attract children and adults together
are likely to be particularly successful. Again, television and popular
magazines and newspapers are important ways of contacting the public.
Clinicians and scientists have traditionally been wary of engaging in
public discussion as they lack the training and the time to do this
and there is some justifiable concern about adversarial journalism.
Training for engagement in public discussion should, however, be part
of medical education and team briefing in healthcare. Novel voices and
talent may be discovered and doctors should not assume that they are
best at communication or closest to patients. These issues are addressed
further in the Society's response on Science and Society.
SECTION 4 - RESEARCH, DEVELOPMENT AND TECHNOLOGY
How might universities and research councils respond to
the challenge of interface innovation?
It is well known that fundamental scientific advances are often the
result of the application of the technologies or concepts of one science
in the territory of another. The Research Councils are already keenly
aware of this and have many interdisciplinary initiatives under way.
In addition, in most research-orientated universities, single-subject
departments have already been replaced by multi-disciplinary research
groupings. Universities do, however, have a problem in developing interdisciplinary
research in the confines of the categorisation of the Research Assessment
Exercise and this needs to be addressed.
Interface innovation could be further supported by providing a flexible
environment that fosters natural collaboration rather than imposing
pre-judged ideas of which interfaces are likely to be most productive;
by providing interdisciplinary courses or course combinations for the
next generation of students; by provision of lifelong learning programmes
where those with expertise in one field can acquire new expertise in
a complementary one; through the establishment of discipline-hopping
research fellowships and through sabbatical leave for senior staff to
facilitate interface innovation.
It would be helpful if each of the foresight panels could identify
two or three hot topics of greatest relevance to health care within
the scope of their review.
Potential topics of greatest relevance to healthcare could
include:
- the identification of effective and safe means of preventing and
stopping the addictive habits of alcohol, cigarettes and drugs;
- the genetic predisposition to cancer and strategies to prevent
cancer;
- tissue engineering, medical biomicrosensor systems, medical microrobotics,
intelligent drug delivery systems and disability aids;
- computerised image analysis techniques for screening (e.g. in cervical
smears and mammography);
- healthy ageing;
- genomics to proteomics (the cell factory);
- food safety, nutrition and environmental health;
- brain development, maintenance, repair and ageing;
- screening (either for genetic disorders or pre-symptomatic disease);
and
- attitudes to termination of life.
There is a clear tension between encouragement of industrial
innovation and resource control through barriers to the entry of new
technologies into healthcare. What steps should be taken to resolve
this in the longer term?
A new technology should only be introduced if it has been proven to
be clearly beneficial and cost effective. However, the NHS is taking
some steps to encourage the introduction of new technology through its
New and Emerging Applications of Technology (NEAT) initiative. The financial
problems represent the most significant barrier to the clinical testing
of new technology internationally.
Technology transfer should be removed from university administration
and developed through an organisation that understands technology and
how to handle, manage, package and market it. Are these realistic and
desirable options and if so how might they be set in place?
The role of the British Technology Group (BTG), and its predecessor,
has been crucial in ensuring that British intellectual property has
been protected, as on their own, universities do not have the financial
power to protect patents. This is an important element in technology
transfer and the panel could explore what can be offered through BTG.
Overall, the success of universities in technology transfer has been
patchy, often the problem being lack of adequate resources and the inability
torecruit staff at competitive rates. On the other hand, local groups
know what is going on within their own institution, be it a university
or a hospital, and are more able to identify opportunities and give
encouragement to potential projects. The concept of an Applied Research
Council is marginally attractive, but funding is not the only issue
and the breadth of its remit would mean it would be difficult for it
to command the expertise required across the whole range of the biological
and physical sciences and engineering. There would be considerable resistance
now to removing technology transfer from the control of the Universities
particularly if financial benefits are likely to accrue to the Universities
from present structures. An alternative could be to provide applied
research panels within existing Research Councils.
What steps are needed to sustain the UK healthcare sector
in a competitive global market, to maintain the UK’s strengths
in clinical research and to prevent a move of trials and industrial
R&D away from the UK?
Regulatory burdens are escalating and a balance needs to be struck between
freedom to undertake research and the necessary constraints around it.
In this context, the need for the Home Office to streamline the handling
of proposals for animal research, without prejudicing animal welfare,
is currently receiving attention. Regulation, however, is not necessarily
bad. In the field of drug regulation, the U.K. is looked on as a strict
but fair regulator and companies are encouraged, rather than discouraged,
by this. If regulation is seen to be excessive, or badly managed, then
this will act as a negative incentive.
In this area, vocal pressure groups are, however, influencing the agenda,
and while much of this is responsible and of proper concern (e.g. prevention
of suffering in experimental animals, illegal retention of organs),
there is also some risk of tabloid journalism and public misunderstanding
constraining future research. The most visible effect of this may be
to drive commercial enterprises to undertake research abroad. There
is a less visible effect of simply deterring many individual researchers
who give up and take a much lower research profile than they would otherwise
have done.
Other important issues include: the need to simplify the processes
of ethical approval, particularly for large, multicentre clinical trials;
the lack of large multinational companies in the UK capable of marketing
medical products, and the need for institutions to moderate the overhead
costs they apply to clinical research.
How might repair and replacement services evolve and what
is the most realistic assessment of their scope in relation to ageing,
chronic disease and injury?
Within the normal lifespan of an individual as we currently understand
it, most ill health is caused by individual parts of the body wearing
out, being injured, developing abnormal growth patterns or initiating
inappropriate immune reactions, asynchronously with the rest of the
body. Successful ageing might well entail transplants, targeted immune
wipe-out, tumour eradication or infection control. By 2020, it may be
possible to harvest and bank currently discarded birth tissues, for
example from the umbilical cord, to serve as a later source of stem
cells for manipulation. In a separate approach, interface research may
allow chemists or engineers to deliver novel non-biological, non-allergenic
materials for use in transplant surgery. Physics and microbiology may
provide novel mechanisms and delivery systems for targeting subcellular
components which require eradication. Such developments are feasible
and of enormous relevance to ageing, chronic disease and injury. These
issues are addressed further in the Society's response on the Chief
Medical Officer’s Expert Group on Cloning.
In anticipation of the use of animal organs (xenografts)
for transplantation into human subjects, how best might the public,
professions and government work together to define acceptable risk in
relation to need?
The issue of xenografts is pressing because it is the closest to realisation
and presents, through the unquantified risk of endogenous viruses, a
possible conflict between individual benefit and community risk. The
current climate of public opinion, reinforced by media concerns, is
not propitious for the exploitation of ethically sensitive research.
As in the case of general healthcare issues, public education can only
be beneficial and this should be a priority. This issues could be further
developed by the UK Xenotransplantation Interim Regulatory Authority
and are addressed further in the Society's response on Animal Tissue
into Humans.
Is the concept of an NHS Clinical Research Organisation
feasible and if so what might its functions and mode of operation be?
The notion of an NHS clinical research organisation is an interesting
one and should be considered. However, there is currently a danger of
an increasing split between NHS and university based research. The status
of NHS research needs enhancing and this kind of role would command
respect. A similar concept has been considered by the House of Commons
Science and Technology Committee Report on Cancer Research, which examined
the feasibility of establishing a National Cancer Institute. The conclusion,
which is equally applicable to a Clinical Research Organisation, is
that such a body is desirable, and should be real rather than virtual
but should not be based on a single site. The concept of a Clinical
Research Organisation concentrated in a number of centres of excellence
seems feasible but the corollary is that NHS R&D funding should
be provided directly to the organisation.
Given the current burden of mental health problems and
social and scientific trends what form might comprehensive community
and hospital-based mental health care take in two decades time?
Mental health problems cannot be considered in isolation either in hospital
or in the community. Greater understanding of the pathogenesis of these
conditions, and the contribution of genetic, developmental and environmental
factors, should focus mental health care on early intervention to reduce
the burden of severe illness. At present, there is considerable pressure
both from government and from the user movement to make the treatment
of mental illness an exclusively community based discipline. There is
a great risk in this of cutting psychiatric services off from developments
in the neurosciences with crucial implications for diagnosis and treatment.
It is already clear, for example, that several forms of brain scanning
are going to be capable of providing information that is likely to be
essential both for diagnosis and the monitoring of treatment within
the next 20 years. The complexityof the potential advances in the prevention
and treatment of neurological illness would seem to point towards the
formation of multidisciplinary regional services to oversee the management
of these advances. Education should also continue to prevent the fear
and stigma associated with mental health problems.
What action should be taken in the short term to place
the UK in a lead position with regard to the longer-term benefits of
genome research?
The exploitation of post genome technology is likely to come from larger
organisations like Government research units or pharmaceutical companies,
and will inform the assessment of individual disease risk. However,
particular discoveries regarding individual genome targets will be within
the province of smallfocused research groups. One initiative that central
policy could take would be to identify the likely deficiencies in progress
where gaps in information might occur. However, UK could also concentrate
resources in areas of strength, such as the understanding of proper
multi-centre trials and meta-analysis both on a UK and European front.
European networks will certainly be required for rare diseases and liaison
with European Union research networks would be beneficial in this area.
In the short term, action could include: increasing the level of both
targeted and response-mode funding for research in this area and in
related interdisciplinary areas; enhancing skills in bioinformatics
and whole-cell biology, including structural molecular biology and ensuring
that the public is made aware of the benefits that can be accrued.
What are the barriers to efficient, appropriate use of
Human Genome Data?
Possible barriers include: patenting of sequence information; the need
for development of, and access to, appropriate information technology;
scarcity and cost of research equipment; adequate research manpower;
ethical issues relating to access to individual's genome data; public
resistance to research and the need to develop efficient, safe, cost-effective
gene therapy procedures.
Theoretical barriers to efficient use of human genome data relate mainly
to interpretation of gene interactions. While moving from the genome
to the proteome should be a rapid process, benefiting from the same
bioinformatics power as was applied to the Human Genome Project, understanding
the interactions of proteins inprocesses at the whole cell level will
probably be a tougher task, yet it is one that must be achieved to acquire
precision in treating disease.
In addition, in order to creating datasets of human genomic material
in relation to clinical syndromes and presenting problems, there will
need to be outcome data of an individual's clinical ill health. However,
while relevant clinical information may be available at the time of
creating a dataset, its full use will require updating, raising problems
both in terms of confidentiality and the manpower to log clinical outcomes.
Since a particular hope is that identification of those
susceptible to specific health problems such as heart disease, cancer
and diabetes in later life will lead to effective preventative strategies,
what steps should be taken to launch large scale population studies?
Large scale population studies are already underway in some areas and
this trend should be encouraged by funding bodies, although proposals
in this area should still be in competition with other research proposals
in order to ensure that the best research is funded over the whole spectrum.
To ensure best use of large patient cohorts, it will also be important
that there is a coherent national approach. Financial incentives to
publicise the existence of data sets, patient cohort groups and genetic
information may help.
What will determine the likely impact of Human Genome R&D
on Healthcare in 2020 and who will determine the need for post-genome
technologies - pharmaceutical companies, government, professionals,
the public or patients?
The impact of the Human Genome research on healthcare will be determined
by a combination of pharmaceutical companies, government, professionals,
public and patients and there should be regular ongoing dialogue between
these groups.
The collation and use of genetic data raises ethical questions which
need to be addressed promptly. As part of this it is important to ask
whose ethical agenda is it, who sets the rules for the majority, and
how might the dissimilar views of different groups be reconciled?
Consideration of bioethical questions has a high profile, and while
this is right and proper, there appears to be too much diversity and
arbitrary ruling in the hands of local research ethics committees. More
general and widely available writing on ethical issues, together with
guidelines for best practice, are to be welcomed and less burdensome
ethical boundaries might be considered. In the UK the legal position
is vague because there have been few test cases. The situation is likely
to be clarified only once some tangible benefit from the collation and
use of genetic data has been demonstrated.
How might society be divided by genetic information?
Society should not be divided by genetic information and biodiversity
should be accepted and welcomed as part of the richness of human existence.
However it is inevitable that in the future some degree of genetic selection
will be employed by parents anticipating the birth of their children.
How might the NHS in partnership with the universities
and industry stimulate the development of new methodology appropriate
to post-genome research and analysis?
The NHS should assemble a task force, together with a suitable funding
budget, to commission appropriate research and new methodology.
Additional Information
In responding to this inquiry the Society would like to draw attention
to the following Royal Society of Edinburgh responses which are of relevance
to this subject: Animal Tissue into Humans (April 1997); Consent and
the Law (December 1997); Cloning Issues in Reproduction, Science and
Medicine (April 1998); Review of the Common Law Provisions Relating
to the Removal of Gametes and of the Consent Provisions in the Human
Fertilisation and Embryology Act 1990 (April 1999); Science and Society
(June 1999); Chief Medical Officer’s Expert Group on Cloning (November
1999) and Preimplantation Genetic Diagnosis (March 2000).
Copies of the above publications and further copies of this response
are available from the Research Officer, Dr Marc Rands
September 2000
Further information is available from the Research Officer, Dr
Marc Rands |